Blood Test Can Measure Effectiveness of Treatments for Aggressive Skin Cancers
Font : A-A+
Note: This presentation at the annual meeting of the American Society of Clinical Oncology, Abstract #259011, is titled: Circulating tumor DNA (ctDNA) kinetics to predict survival in patients with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T). The study will be presented in the Clinical Science Symposium: Next-Generation Therapeutics and Biomarkers in Melanoma session on Saturday, June 1, 2019, from 3PM to 4:30 PM CDT.
Post your Comments
Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer